FilingReader Intelligence
Jinyu Bio-Technology shares jump on vaccine trial approval
July 18, 2025 at 05:00 AM UTC•By FilingReader AI
Jinyu Bio-Technology shares rose over 20% in three days following its subsidiary's clinical trial approval for an African Swine Fever subunit vaccine.
The company invested approximately 64 million yuan in developing the vaccine. However, Jinyu projects a significant decline in first-half 2025 net profit.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jinyu Bio-Technology publishes news
Free account required • Unsubscribe anytime